SRZN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration...

Stats
今日成交量	11 124.00
平均成交量	16 966.00
市值	28.72M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-4.25 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.420
ATR14	$0.150 (1.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Li Yang	Buy	10 000	Option (right to buy)
2024-04-24	Li Yang	Buy	5 000	Restricted Stock Unit
2024-04-24	Parker Craig C	Buy	43 000	Option (right to buy)
2024-04-24	Williams Charles O	Buy	13 000	Option (right to buy)
2024-04-24	Williams Charles O	Buy	7 000	Restricted Stock Unit

INSIDER POWER
92.41
Last 99 transactions
Buy: 7 137 981 \| Sell: 808 309

Surrozen, Inc. 相关性

10 最正相关
NXTC	0.94
PVBC	0.939
TOI	0.936
HHGCU	0.933
STSA	0.916
JNCE	0.916
PRVA	0.915
FAAR	0.909
VSTA	0.903
LPTX	0.9

10 最负相关
NRIM	-0.942
AMRB	-0.937
MDLZ	-0.928
CLRO	-0.928
LYLT	-0.923
STIM	-0.917
PBFS	-0.904
PRDO	-0.903
VLYPO	-0.901
LVHD	-0.901

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Surrozen, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2023
营收:	$0
毛利润:	$-1.91M (0.00 %)
EPS:	$-21.33

FY	2022
营收:	$12.50M
毛利润:	$9.23M (73.85 %)
EPS:	$-11.95

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.556

Financial Reports:

No articles found.

Surrozen, Inc.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.